

Câncer de Ovário (Epitelial)

Ciclofosfamida + Carboplatina

Ciclofosfamida: 600mg/m² IV D1
Carboplatina: 300mg/m² IV D1 a cada 28 dias X 6 ciclos
Ref. (1)

Ciclofosfamida + Cisplatina

Ciclofosfamida: 600mg/m² IV D1
Cisplatina: 100mg/m² IV D1 a cada 28 dias X 6 ciclos
Ref. (2)

Cisplatina + Paclitaxel

Cisplatina: 75mg/m² IV D1
Paclitaxel: 135mg/m² IV D1 em 24 horas de infusão
a cada 21 dias X 6 ciclos
Ref. (3)

OU

Paclitaxel: 175mg/m² IV D1 a cada 21 dias X 6 ciclos

Carboplatina + Paclitaxel

Carboplatina: AUC 5 a 7 IV D1
Paclitaxel: 175mg/m² IV D1 a cada 21 dias X 6 ciclos
Ref. (4)

Carboplatina + Docetaxel

Carboplatina: AUC 6 IV D1
Docetaxel: 60mg/m² IV D1 a cada 21 dias X 6 ciclos
Ref. (5)

Cisplatina + Gencitabina

Cisplatina: 30mg/m² IV D1 e D8

Gencitabina: 750mg/m² IV D1 e D8 a cada 21 dias X 6 ciclos

Ref. (6)

Doxorrubicina Lipossomal

Doxo Lipossomal: 40-50mg/m² IV D1 a cada 28 dias

Ref. (7-9)

Gencitabina

Gencitabina: 1000mg/m² IV D1, D8, D15 a cada 21 dias

Ref. (9)

Paclitaxel

Paclitaxel: 135-170mg/m² IV D1 a cada 21 dias

Ref. (10)

OU

Paclitaxel: 80mg/m² IV D1, D8 e D15 a cada 28 dias

Topotecano

Topotecano: 1,5mg/m² IV D1 a D5 a cada 21 dias

Ref. (11)

Topotecano: 2,5 a 4mg/m² IV D1, D8, D15 a cada 28 dias

Ref. (12)

Etoposide

Etoposide: 50mg/m²/dia VO D1 a D21 a cada 28 dias

Ref. (13)

Carboplatina

Carboplatina: AUC 6 IV D1 a cada 21 dias
Ref. (14)

Vinorelbina

Vinorelbina: 25mg/m² IV D1, D8, D15 a cada 21 dias
Ref. (15)

Tamoxifeno

Tamoxifeno: 20mg VO Contínuo
Ref. (16)

Quimioterapia intraperitoneal (estágio III)

Paclitaxel: 135 mg/m² IV em 24h D1
Cisplatina: 100 mg/m² IP D2
Paclitaxel: 60 mg/m² IP D8 a cada 21 dias por 6 ciclos
Ref. (18)

Docetaxel

Docetaxel: 100mg/m² IV D1 21 dias
Ref. (19)

Oxaliplatina

Oxaliplatina: 100 mg/m² IV D1 21 dias
Ref. (20)

TIP

Paclitaxel: 250 mg/m² em 24 horas IV D1
Ifosfamida: 1.200 mg/m² IV D2 –D6
Mesna : 400 mg/m² IV nas horas 0,4 e 8 da Ifosfamida D2-D6
Cisplatina: 20 mg/m² IV D2-D6 a cada 21 dias.
Ref. (21)

VeIP

Vinblastina: 0,1 mg/kg IV D1-D2

Ifosfamida: 1,200 mg/m² IV D1 -D5

Mesna : 400 mg/m² IV nas horas 0,4 e 8 da Ifosfamida D1-D5

Cisplatina: 20 mg/m² IV D1-D5

Ref. (22)

Câncer de Ovário (Tumor de Células Germinativas)

BEP

Cisplatina: 20mg/m² IV D1-D5

Etoposide: 100mg/m² IV D1-D5

Bleomicina: 30UI IV D2, D9,D16 a cada 21 dias

Ref. (17)

1. Swenerton, K., *et al.* Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol*, 1992. 10(5): p. 718-26.
2. Alberts, D.S., *et al.* Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. *J Clin Oncol*, 1992. 10(5): p. 706-17.
3. McGuire, W.P., *et al.* Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med*, 1996. 334(1): p. 1-6.
4. Ozols, R.F., Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. *Semin Oncol*, 1995. 22(6 Suppl 15): p. 1-6.
5. Markman, M., *et al.* Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. *J Clin Oncol*, 2001. 19(7): p. 1901-5.

6. Nagourney, R.A., *et al.* Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients. *Gynecol Oncol*, 2003. 88(1): p. 35-9.
7. Gordon, A.N., *et al.* Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. *J Clin Oncol*, 2001. 19(14): p. 3312-22.
8. Rose, P.G., *et al.* Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages. *Gynecol Oncol*, 2001. 82(2): p. 323-8.
9. Ferrandina, G., *et al.* Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. *J Clin Oncol*, 2008. 26(6): p. 890-6.
10. McGuire, W.P., *et al.* Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. *Ann Intern Med*, 1989. 111(4): p. 273-9.
11. Kudelka, A.P., *et al.* Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. *J Clin Oncol*, 1996. 14(5): p. 1552-7.
12. Bhoola, S.M., *et al.* Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer. *Gynecol Oncol*, 2004. 95(3): p. 564-9.
13. Ozols, R.F., Oral etoposide for the treatment of recurrent ovarian cancer. *Drugs*, 1999. 58 Suppl 3: p. 43-9.
14. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. *Lancet*, 2002. 360(9332): p. 505-15.
15. Bajetta, E., *et al.* Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. *J Clin Oncol*, 1996. 14(9): p. 2546-51.
16. Kristensen, g., Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study journal of clinical oncology, 2008. 26(supplement): p. abst5508.

- 17.** Dimopoulos, M.A., *et al.* Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. *Gynecol Oncol*, 2004. 95(3): p. 695-700.
- 18.** Armstrong Dk, *et al.* Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. *New Engl Med* 2006;354:34-43.
- 19.** Kaye SS, *et al.* Is cisplatin-taxol (PT) the standard treatment in advanced ovarian cancer. *Eur J Cancer* 1997;31-2167-70.
- 20.** ChOllet P, *et al.* Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer *Ann Oncol* 1996; 7: 1065-70.
- 21.** Motzer RJ, Sheinfeld J, Mazumdar M, *et al.* Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. *J Clin Oncol*. 2000;18:2413-2418.
- 22.** McCaffrey JA, Mazumdar M, Bajorin DF, *et al.* Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. *J Clin Oncol* . 1997; 15:2559-2563.